Date: 2011-08-11
Type of information: Licensing agreement
Compound: EVT401
Company: Evotec (Germany) undisclosed tier animal health company
Therapeutic area: Veterinary diseases
Type agreement: licensing collaboration
Action mechanism:
Disease:
Details: Evotec has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market. Evotec is entitled to receive a technology- transfer payment, development and commercial milestone payments, and tiered royalties on net sales. Evotec retains all rights to the programme for human therapeutic use.
Financial terms: Financial details were not disclosed.
Latest news:
